MicroPort CardioFlow Medtech Corp. (HK:2160) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
MicroPort CardioFlow Medtech Corporation reports a promising interim revenue of RMB 215-225 million for the first half of 2024, marking a significant increase of 22-28% from the previous year. This surge is credited to the successful expansion of their TAVI products in China, the launch of the AnchorMan system, and increased international sales, including new market entries and obtaining the CE certificate in Europe. The company also emphasizes its strategic focus on resource allocation, advancing key projects, and stringent cost control measures aimed at achieving operational breakeven.
For further insights into HK:2160 stock, check out TipRanks’ Stock Analysis page.